Skip to main content

Table 1 Clinical and laboratory characteristics of the SLE patients studied

From: Phenotypic and functional abnormalities of bone marrow-derived dendritic cells in systemic lupus erythematosus

Case Current treatment WBC (×109/L) Hb (g/dL) Plt (×109/L) Lym (×109/L) Anti-dsDNA Serum C3 Serum C4 24-hour UP SLE-DAI
1 HCQ 200 mg/d 3.8 16.3 23 1.3 <5 54 13 0.24 3
2 Pred 5 mg/d, HCQ 200 mg/d 2.04 8.6 352 1.04 18 80 15 NA 1
3 Pred 12.5 mg/d, MMF 3 mg/d 10.55 9.2 281 0.45 34 72 24 6.57 6
4 HCQ 300 mg/d 2.38 12.1 149 0.64 127 29 7.1 <0.06 16
5 Pre 15 mg/d, HCQ 200 mg/d, Aza 100 mg/d 0.8 8.9 67 .3 19 94 19 0.18 6
6 Pred 20 mg/d, HCQ 400 mg/d 1.93 11.5 131 0.49 54 36 2.9 NA 15
7 Pred 7.5 mg/d, Aza 50 mg/d, MMF 1 mg/d 2.3 9.0 70 0.2 150 27 9.9 0.26 15
8 Pred 20 mg/d 4.9 10.4 207 1.4 9 67 13 NA 6
9 HCQ 200 mg/d 2.06 7.4 94 0.82 85 31 5.3 3.63 13
10 Pred 12.5 mg/d MMF 3 g/d 6.0 12.0 74 0.6 45 58 27 0.11 15
11 Pred 50 mg/d 3.54 9.4 47 0.9 29 101 34 NA 2
12 Pred 15 mg/d, HCQ 200 mg/d, Aza 100 mg/d 5.21 11.6 31 0.25 12 109 23 NA 1
13 HCQ 300 mg/d 4.1 9.5 92 1.2 >450 26 3.7 2.4 14
  1. F, female; Pred, prednisolone;HCQ, hydroxychloroquine;Aza, azathioprine;MMF, mycophenolate mofetil;Hb, hemoglobin; WBC, white blood cell count [NR 4.1-10.9 × 109/L]; Plt, platelet count [NR 140-450 × 109/L]; Lym, lymphocyte count [NR 20-50% of WBCs]; SLEDAI, systemic lupus erythematosus disease activity index.